These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 32917511)

  • 1. Maximizing Impact: Can Interventions to Prevent Clinical Malaria Reduce Parasite Transmission?
    McCann RS; Cohee LM; Goupeyou-Youmsi J; Laufer MK
    Trends Parasitol; 2020 Nov; 36(11):906-913. PubMed ID: 32917511
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mass campaigns combining antimalarial drugs and anti-infective vaccines as seasonal interventions for malaria control, elimination and prevention of resurgence: a modelling study.
    Camponovo F; Ockenhouse CF; Lee C; Penny MA
    BMC Infect Dis; 2019 Oct; 19(1):920. PubMed ID: 31664924
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Seasonal use case for the RTS,S/AS01 malaria vaccine: a mathematical modelling study.
    Thompson HA; Hogan AB; Walker PGT; Winskill P; Zongo I; Sagara I; Tinto H; Ouedraogo JB; Dicko A; Chandramohan D; Greenwood B; Cairns M; Ghani AC
    Lancet Glob Health; 2022 Dec; 10(12):e1782-e1792. PubMed ID: 36400084
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development and Evaluation of a Cryopreserved Whole-Parasite Vaccine in a Rodent Model of Blood-Stage Malaria.
    Stanisic DI; Ho MF; Nevagi R; Cooper E; Walton M; Islam MT; Hussein WM; Skwarczynski M; Toth I; Good MF
    mBio; 2021 Oct; 12(5):e0265721. PubMed ID: 34663097
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Seasonal malaria vaccination: protocol of a phase 3 trial of seasonal vaccination with the RTS,S/AS01
    Chandramohan D; Dicko A; Zongo I; Sagara I; Cairns M; Kuepfer I; Diarra M; Tapily A; Issiaka D; Sanogo K; Mahamar A; Sompougdou F; Yerbanga S; Thera I; Milligan P; Tinto H; Ofori-Anyinam O; Ouedraogo JB; Greenwood B
    BMJ Open; 2020 Sep; 10(9):e035433. PubMed ID: 32933955
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Malaria vaccines: past, present and future.
    von Seidlein L; Bejon P
    Arch Dis Child; 2013 Dec; 98(12):981-5. PubMed ID: 24061779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vaccines against malaria-still a long way to go.
    Matuschewski K
    FEBS J; 2017 Aug; 284(16):2560-2568. PubMed ID: 28500775
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Towards clinical development of a Pfs48/45-based transmission blocking malaria vaccine.
    Theisen M; Jore MM; Sauerwein R
    Expert Rev Vaccines; 2017 Apr; 16(4):329-336. PubMed ID: 28043178
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Simulated impact of RTS,S/AS01 vaccination programs in the context of changing malaria transmission.
    Brooks A; Briët OJ; Hardy D; Steketee R; Smith TA
    PLoS One; 2012; 7(3):e32587. PubMed ID: 22412892
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The march toward malaria vaccines.
    Hoffman SL; Vekemans J; Richie TL; Duffy PE
    Vaccine; 2015 Nov; 33 Suppl 4(Suppl 4):D13-23. PubMed ID: 26324116
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antimalarial Transmission-Blocking Interventions: Past, Present, and Future.
    Delves MJ; Angrisano F; Blagborough AM
    Trends Parasitol; 2018 Sep; 34(9):735-746. PubMed ID: 30082147
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multistage inhibitors of the malaria parasite: Emerging hope for chemoprotection and malaria eradication.
    Poonam ; Gupta Y; Gupta N; Singh S; Wu L; Chhikara BS; Rawat M; Rathi B
    Med Res Rev; 2018 Sep; 38(5):1511-1535. PubMed ID: 29372568
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transmission blocking malaria vaccines: Assays and candidates in clinical development.
    Sauerwein RW; Bousema T
    Vaccine; 2015 Dec; 33(52):7476-82. PubMed ID: 26409813
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of RTS,S/AS02(A) and RTS,S/AS01(B) on genotypes of P. falciparum in adults participating in a malaria vaccine clinical trial.
    Waitumbi JN; Anyona SB; Hunja CW; Kifude CM; Polhemus ME; Walsh DS; Ockenhouse CF; Heppner DG; Leach A; Lievens M; Ballou WR; Cohen JD; Sutherland CJ
    PLoS One; 2009 Nov; 4(11):e7849. PubMed ID: 19924281
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Erythroid cells and malaria parasites: it's a match!
    Neveu G; Lavazec C
    Curr Opin Hematol; 2021 May; 28(3):158-163. PubMed ID: 33631784
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent developments in malaria vaccinology.
    Halbroth BR; Draper SJ
    Adv Parasitol; 2015 Apr; 88():1-49. PubMed ID: 25911364
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Malaria Elimination: Time to Target All Species.
    Lover AA; Baird JK; Gosling R; Price RN
    Am J Trop Med Hyg; 2018 Jul; 99(1):17-23. PubMed ID: 29761762
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modelling the relative cost-effectiveness of the RTS,S/AS01 malaria vaccine compared to investment in vector control or chemoprophylaxis.
    Topazian HM; Schmit N; Gerard-Ursin I; Charles GD; Thompson H; Ghani AC; Winskill P
    Vaccine; 2023 May; 41(20):3215-3223. PubMed ID: 37080831
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Loss of population levels of immunity to malaria as a result of exposure-reducing interventions: consequences for interpretation of disease trends.
    Ghani AC; Sutherland CJ; Riley EM; Drakeley CJ; Griffin JT; Gosling RD; Filipe JA
    PLoS One; 2009; 4(2):e4383. PubMed ID: 19198649
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.